## For Research Use Only

## Recombinant Mouse PCSK9 protein (His Tag)



www.ptgcn.com

Catalog Number: Eg0640

**Basic Information** 

Species: Mouse

Purity: >90 %, SDS-PAGE

Tag: His Tag

**Technical Specifications** 

Purity: >90 %, SDS-PAGE

**Endotoxin Level:** 

<0.1 EU/ µ g protein, LAL method

HEK293-derived Mouse PCSK9 protein Gln35-Gln694 (Accession# Q80W65) with a His tag at the C-terminus.

GeneID: 100102

080W65

Predicted Molecular Mass: 13.9 kDa (Propeptide) and 58.1 kDa (mature chain)

17 kDa (Propeptide) and 55-65 kDa (mature chain), reducing (R) conditions

Lyophilized from 0.22  $\,\mu$  m filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.

**Biological Activity** 

Not tested

Storage and Shipping

It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

Until expiry date, -20°C to -80°C as lyophilized proteins.

3 months, -20℃ to -80℃ under sterile conditions after reconstitution.

The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Reconstitution

Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.

Background

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a crucial protein governing the circulating levels of low density lipoprotein-cholesterol (LDL-C), by virtue of its pivotal role in the degradation of the LDL receptor (LDLR). PCSK9 is expressed in the kidney and lung. It is synthesized as a 72 kDa immature precursor that undergoes autocatalytic cleavage in the endoplasmic reticulum to generate a 63 kDa mature protein. The cleaved N-terminal fragment remains associated with the mature protein and is necessary for its secretion, allowing it to circulate in the blood. The ability of PCSK9 to regulate a diverse group of cell-surface proteins hinted that it might also be able to influence additional membrane proteins that are important in antitumour immune responses. Targeting PCSK9 to treat cancer is also attractive because two neutralizing antibodies against it, evolocumab and alirocumab, have already been approved for human clinical use to lower cholesterol levels.


References

- Blanchard, Valentin et al. "PCSK9: from biology to clinical applications." Pathologyvol. 51,2 (2019): 177-183. doi:
  Sharotri, Vikas et al. "Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/k
  Canuel, Maryssa et al. "Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the la

**Synonyms** 

PCSK9, Al415265, Al747682, FH3, HCHOLA3

## **Selected Validation Data**



Purity of Recombinant Mouse PCSK9 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.